8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 27, 2026·SEC
Pulse Biosciences, Inc.(PLSE)Earnings, Financials & Key Ratios
PLSE•NASDAQ
$28.03
Price updated Jul 7, 2026
AboutPulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Show more
- Revenue$350K
- EBITDA-$76M-37.7%
- Net Income-$73M-35.8%
- EPS (Diluted)-1.08-17.4%
- Gross Margin-360%
- EBITDA Margin-21676.57%
- Operating Margin-21982.57%
- Net Margin-20794.57%
- ROE-74.45%-10.6%
PLSE Price & Volume
Pulse Biosciences, Inc. (PLSE) stock price & volume — 10-year historical chart
Loading chart...
Nascent Commercialization Faces Persistent Clinical Burn Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Pulse Biosciences is currently navigating a high-risk transition from a pure-play R&D entity to a commercial-stage medical device company, characterized by significant quarterly cash outflows of approximately $14.6 million.
- While the company maintains a relatively clean balance sheet with a debt-to-equity ratio of 0.11, the lack of consistent revenue growth and negative gross margins suggest that the underlying business model has yet to achieve commercial viability.
- Investors should monitor the company's ability to scale its nanosecond pulse power platform while managing the substantial $12.6 million in quarterly R&D expenses that continue to drive cumulative deficits of $481.9 million.
Verdict Logic
the company's inability to generate consistent revenue, evidenced by a 2026Q1 operating margin of -47.8%, suggests that the current valuation is not supported by fundamental commercial performance.
PLSE Growth Metrics
Pulse Biosciences, Inc. (PLSE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-20.63%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.1%
Return on Capital
10 Years-88.26%
5 Years-92.97%
3 Years-69.17%
Last Year-73.07%
PLSE Recent Earnings
Pulse Biosciences, Inc. (PLSE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.27+15.6%
$0.32
Rev
$400,000+60.0%
$250,000
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.26+1.9%
$0.27
Rev
$264,000+76.0%
$150,000
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.29+6.5%
$0.31
Rev
$86,000-61.8%
$225,000
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.28-7.7%
$0.26
Rev
—
$500,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.27vs $0.32+15.6% | $400,000vs $250,000+60.0% |
| Q1 2026 | Feb 19, 2026 | $0.26vs $0.27+1.9% | $264,000vs $150,000+76.0% |
| Q4 2025 | Nov 5, 2025 | $0.29vs $0.31+6.5% | $86,000vs $225,000-61.8% |
| Q3 2025 | Aug 12, 2025 | $0.28vs $0.26-7.7% | —vs $500,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pulse Biosciences, Inc. (PLSE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.03 | $1.94B | -25.95 | — | -20794.57% | -74.45% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $67.33 | $2.9B | -146.36 | 157.01% | -11.53% | — | — | |
| $14.54 | $921.24M | 10.17 | -6.16% | 23.27% | 13.28% | — |
Compare PLSE vs Peers
Pulse Biosciences, Inc. (PLSE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PLSE SEC Filings & Documents
Pulse Biosciences, Inc. (PLSE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PLSE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PLSE Frequently Asked Questions
Pulse Biosciences, Inc. (PLSE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Pulse Biosciences, Inc.'s revenue?
Pulse Biosciences, Inc. (PLSE) reported $0.8M in revenue for fiscal year 2025.
Is PLSE profitable?
Pulse Biosciences, Inc. (PLSE) reported a net loss of $74.6M for fiscal year 2025.
Dividend & Returns
What is PLSE's return on equity?
Pulse Biosciences, Inc. (PLSE) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.
What is Pulse Biosciences, Inc.'s free cash flow?
Pulse Biosciences, Inc. (PLSE) had negative free cash flow of $55.5M in fiscal year 2025, likely due to heavy capital investments.